Clinical Studies

COMISAIR Study Shows that CGM—Not the Insulin Delivery Method—Drives A1C Reduction

You are here

In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on multiple daily injection (MDI) regimen vs. insulin pump therapy. Results from this year-long study challenged the notion that patients on MDI would not benefit as significantly from CGM use those on an insulin pump. Furthermore, this study presented convincing evidence that CGM – not the insulin delivery method – drives A1C reduction.

Source: Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.

View the article.

More Clinical Studies

This paper reviews the features and available evidence supporting use of both real-time continuous glucose monitoring (rtCGM) and intermittent scanning CGM (isCGM), offering guidance for patient selection for each type of system. RtCGM systems (...

HypoDE study shows that Dexcom CGM use significantly reduces hypoglycemia in MDI patients.1 Background

Continuous glucose monitoring (CGM) clinical trials to date have largely excluded individuals with severe hypoglycemia (SH) or...

In hypoglycemia unaware patients, CGM provides the required information needed for enhanced decision making support to improve glycemic control and help eliminate severe hypoglycemia. In this observational study, severe hypoglycemia incidents...